Affinity Asset Advisors, LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

  • $735 Million
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$6.1 - $7.15 $2.44 Million - $2.86 Million
-400,000 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$8.02 - $11.0 $160,400 - $220,000
20,000 Added 5.26%
400,000 $2.11 Million
Q1 2021

May 14, 2021
BUY
$6.86 - $9.24 $1.8 Million - $2.43 Million
262,455 Added 223.28%
380,000 $2.7 Million
Q4 2020

Feb 12, 2021
BUY
$5.0 - $7.5 $587,725 - $881,587
117,545 New
117,545 $918,000

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email